Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Vertex Pharmaceuticals (VRTX) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.56%.For the last ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT. “ 2023 was marked by continued strong performance in the cystic fibrosis business and acceleration of our development stage pipeline, propelling the company into 2024 with tremendous momentum ...

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals (VRTX 0.59%) is modeling right now.Thanks to its long-standing dominance in a key niche market, its newfound pursuit of powerful gene therapies, and its cash output, there's good reason to be excited about the stock. So here are three arguments for why it's worth buying now.1. Its base of recurring revenue is ro ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Jefferies Global Healthcare Conference Call November 14, 2023 3:30 AM ET Company Participants Stuart Arbuckle - Executive Vice President and Chief Operating Officer Conference Call Participants Michael Yee - Jefferies Michael Yee All right. Good morning, everybody. Thank you for joining us here on a beautiful morning session here at the Jefferies Global Healthcare Conference here in London. I'm Michael Yee, one of the senior biotechnology analyst here at Jef ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) UBS Biopharma Conference November 9, 2023 12:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants Colin Bristow - UBS Colin Bristow Good afternoon, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts here. It's my pleasure to have Vertex Pharmaceuticals with us here today. On behalf of the company, we ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2023 Earnings Call Transcript November 6, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President of Investor Relations Reshma Kewalramani - President & Chief Executive Officer Stuart Arbuckle - Executive Vice President & Chief Operating Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Conference Call Participants Geoff Meacham - Bank of America Robyn Karnauskas - Truist Securities Salveen Richter - Goldman ...

THIRD QUARTER 2023 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX On track to complete Ph3 bunionectomy and single arm safety and effectiveness trial by end of 2023 • Granted Fast Track and Breakthrough Therapy designations ©2023 Vertex Pharmaceuticals Incorporated Each stage can take several months | --- | --- | --- | |-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Ph ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 13, 2023 11:30 AM ET Company Participants Charlie Wagner - EVP and CFO Reshma Kewalramani - President and CEO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Well, thanks, everybody, for joining us. I'm Terence Flynn from the U.S. biopharma analyst here at Morgan Stanley and we're very pleased to be hosting Vertex for this session. Today from the company, we have ...

SECOND QUARTER 2023 FINANCIAL RESULTS AUGUST 1, 2023 ©2023 Vertex Pharmaceuticals Incorporated VERTEX AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR ...